SEATTLE--(BUSINESS WIRE)--The Washington Biotechnology & Biomedical Association, the state’s life sciences trade association, announced that its board of directors has appointed ten new members.
Rob Coppedge, SVP, Strategic Investment & Corporate Development, Cambia Health Solutions; Ralph Derrickson, CEO, Carena, Inc.; Rhonda Rhyne, CEO, Prevencio, Inc; Jary Krauser, CEO, StratusG Consulting; David Lowrance, CFO, Acucela Inc.; Caitlin Cameron, CEO, OtoMetrix Medical Technologies, Inc.; Frank Velázquez, MD, President & CEO, Pathology Associates Medical Laboratories (PAML, LLC); Matt Stupfel, VP & General Manager, EKOS Corporation; Jonathon Norris, Managing Director, Life Sciences, Silicon Valley Bank; and Ron Myers, Chief Legal Officer & VP of Strategic Partnerships, Institute for Systems Biology, joined the board, effective July 1, 2014.
In making the announcement on behalf of the Washington Biotechnology & Biomedical Association (WBBA) Board of Directors, Chris Rivera, President & CEO, said, “We are very pleased to have recruited the very best, most talented leaders to our already outstanding board. These additions to the board reflect the diversity in the membership of the WBBA that includes organizations in biotechnology, medical technology, global health, research, academia, bio-agriculture, bio-fuel, and one of our fastest-growing membership segments, digital health. Our membership covers the full spectrum of life sciences in the world today – the WBBA has long ceased representing just biotechnology and biomedical organizations, as our name suggests.”
“These new directors also demonstrate the commitment that our state’s top leaders have in supporting the growth and innovation in Washington’s life sciences ecosystem,” Rivera added. “This is one of the most exciting times to be in the life science industry, as Washington is quickly becoming recognized for its global leadership position. Our new board members will add great value as we continue to support our mission, to help grow and support the life sciences in the state of Washington.”
About the WBBA
The Washington Biotechnology & Biomedical Association (WBBA) has over 630 member organizations and is an independent, non-profit 501(c)(6) trade association serving the life sciences industry in the state of Washington. It is completely resourced and supported by its members, including organizations engaged in, or supportive of, research, development and commercialization of life science innovation.
The WBBA’s mission “to support and help to grow Washington State's life science ecosystem” drives its core strategic focus on:
- Commercialization – Mentoring start-up life science companies that eventually raise capital, commercialize IP and employ people.
- Access to capital – Not just financial capital, but also intellectual, as well as human capital is a top priority for us on behalf of our members.
- Human Capital – Initiatives focused on the recruitment, retention and the development of the talent needed to grow our life science community.
- Public Policy - We advocate for, and increase awareness about, our life sciences sector to our local, state and federal representatives.
- Purchasing Power - Our members save money by purchasing goods and services from our 18 purchasing partners.